Quantcast

Latest Biosimilar Stories

2014-05-13 16:29:25

DUBLIN, May 13, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo(®) (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity....

2014-05-12 08:31:48

REDWOOD CITY, Calif., May 12, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Lisa M. Bell, Ph.D. as Senior Vice President, Global Regulatory Affairs. Dr. Bell joins Coherus with more than 15 years of experience in global regulatory affairs and drug development across various therapeutic areas at preeminent biotech companies. "Lisa brings a strong strategic, scientific and global mindset to the regulatory strategy for our...

2014-05-12 08:31:42

DUBLIN, May 12, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya(® )(clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%. Acanya(®) Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant...

2014-05-10 23:01:06

Many pharmaceutical manufacturers will likely derive sales volumes from biological drugs, while also contending with the entrance of biosimilar, or generic biological drugs, into the market. For these reasons, industry research firm IBISWorld has updated a report on the Brand Name Pharmaceutical Manufacturing industry in its growing industry report collection. New York, NY (PRWEB) May 10, 2014 Brand-name pharmaceutical manufacturers have grappled with one of the largest waves of drug...

2014-05-09 20:23:13

DUBLIN, May 10, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/xrtmp7/global) has announced the addition of the "Global Biosimilars Market 2014-2018" [http://www.researchandmarkets.com/research/xrtmp7/global ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key...

2014-05-02 23:00:27

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides (http://www.marketsandmarkets.com/Market-Reports/biosimilars-40.html). (PRWEB) May 03, 2014 Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast...

2014-04-28 08:31:55

REDWOOD CITY, Calif., April 28, 2014 /PRNewswire/ -- Coherus Biosciences, Inc. ("Coherus"), is pleased to announce the appointment of Michael A. Fleming as Senior Vice President, Commercial Strategy. Mr. Fleming joins Coherus with more than 25 years of experience in strategic and operational leadership roles at preeminent biotech companies. "Michael is a vital addition to the Coherus team at this time," said Denny Lanfear, President and CEO of Coherus. "Our pipeline is now...

2014-04-25 04:22:17

LONDON, April 25, 2014 /PRNewswire/ -- Turkey, with its ambitious social and economic roadmap, is regarded as a rising star in the region. Its drive to promote pharmaceutical innovation, R&D and capital investment makes it the perfect meeting place for local Turkish and regional drug manufacturers to connect and strategize how best to take advantage of the huge opportunities which are available throughout the pharmaceutical supply chain. CPhI, the leading organizer...

2014-04-23 12:29:37

New Entity YL Biologics to focus on clinical development and commercialization of Biosimilars for Japan MUMBAI and BALTIMORE, April 23, 2014 /PRNewswire/ -- Pharma Major, Lupin Limited (Lupin) announced today that it has entered into a strategic joint venture agreement with Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo) to create a new entity, YL Biologics (YLB). YLB will be jointly managed by both partners and will be responsible for conducting...

2014-04-22 12:27:06

Brazilian Public-Private Partnerships Drive Strong Growth in Biosimilars Pipeline, According to Findings from Decision Resources Group BURLINGTON, Mass., April 22, 2014 /PRNewswire/ -- Decision Resources Group finds that the number of publically disclosed biosimilar development projects has increased by more than 40 percent in the last 12 months. The majority of these development projects are yet to enter clinical development, but the 20 percent annual increase in the number of biosimilars in...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related